| Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia AW Roberts, MS Davids, JM Pagel, BS Kahl, SD Puvvada, JF Gerecitano, ... New England Journal of Medicine 374 (4), 311-322, 2016 | 2174 | 2016 |
| Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma MS Davids, AW Roberts, JF Seymour, JM Pagel, BS Kahl, WG Wierda, ... Journal of Clinical Oncology 35 (8), 826-833, 2017 | 806 | 2017 |
| Ipilimumab for patients with relapse after allogeneic transplantation MS Davids, HT Kim, P Bachireddy, C Costello, R Liguori, A Savell, ... New England Journal of Medicine 375 (2), 143-153, 2016 | 609 | 2016 |
| PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer A Glaviano, ASC Foo, HY Lam, KCH Yap, W Jacot, RH Jones, H Eng, ... Molecular cancer 22 (1), 138, 2023 | 577 | 2023 |
| Small molecules, big impact: 20 years of targeted therapy in oncology PL Bedard, DM Hyman, MS Davids, LL Siu The Lancet 395 (10229), 1078-1088, 2020 | 505 | 2020 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 442 | 2018 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 436 | 2021 |
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition JA Burger, DA Landau, A Taylor-Weiner, I Bozic, H Zhang, K Sarosiek, ... Nature communications 7 (1), 11589, 2016 | 399 | 2016 |
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ... The Lancet Oncology 18 (2), 230-240, 2017 | 398 | 2017 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 385 | 2018 |
| Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial S Stilgenbauer, B Eichhorst, J Schetelig, P Hillmen, JF Seymour, S Coutre, ... Journal of Clinical Oncology 36 (19), 1973-1980, 2018 | 366 | 2018 |
| The public repository of xenografts enables discovery and randomized phase II-like trials in mice EC Townsend, MA Murakami, A Christodoulou, AL Christie, J Köster, ... Cancer cell 29 (4), 574-586, 2016 | 354 | 2016 |
| Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity BL Lampson, SN Kasar, TR Matos, EA Morgan, L Rassenti, MS Davids, ... Blood, The Journal of the American Society of Hematology 128 (2), 195-203, 2016 | 341 | 2016 |
| The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism MA Anderson, J Deng, JF Seymour, C Tam, SY Kim, J Fein, L Yu, ... Blood, The Journal of the American Society of Hematology 127 (25), 3215-3224, 2016 | 340 | 2016 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 324 | 2020 |
| Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies R Guièze, VM Liu, D Rosebrock, AA Jourdain, M Hernández-Sánchez, ... Cancer cell 36 (4), 369-384. e13, 2019 | 310 | 2019 |
| Targeting the B-cell lymphoma/leukemia 2 family in cancer MS Davids, A Letai Journal of clinical oncology 30 (25), 3127-3135, 2012 | 307 | 2012 |
| Blastic plasmacytoid dendritic cell neoplasm is dependent on BCL2 and sensitive to venetoclax J Montero, J Stephansky, T Cai, GK Griffin, L Cabal-Hierro, K Togami, ... Cancer discovery 7 (2), 156-164, 2017 | 213 | 2017 |
| Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase MS Davids, JR Brown Future oncology 10 (6), 957-967, 2014 | 204 | 2014 |
| Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia J Deng, E Isik, SM Fernandes, JR Brown, A Letai, MS Davids Leukemia 31 (10), 2075-2084, 2017 | 203 | 2017 |
